Teva Tries its Luck with Risky NGF Inhibitor Class by Partnering with Regeneron
By Jawala Prasad
Pharma Deals Review: Vol 2016 Issue 10 (Table of Contents)
Published: 13 Oct-2016
DOI: 10.3833/pdr.v2016.i10.2201 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Teva Pharmaceutical Industries has entered a development field abandoned by a number of big pharma companies by joining forces with Regeneron Pharmaceuticals to develop fasinumab (REGN475), an anti-NGF (nerve growth factor) antibody that is in Phase III development for osteoarthritis pain and Phase II for chronic low back pain...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS